Pulmo BioTech Reveals Its PulmoBind(TM) Pulmonary Vascular Diagnostic Product Candidate May Apply to Early Stage Diagnosis of Conditions Afflicting Pulmonary Circulation in Pediatric Population

Published: Jun 07, 2010

NEW YORK, June 7, 2010 (GLOBE NEWSWIRE) -- "Pulmo BioTech Inc. (OTCBB:PLMO) (Frankfurt:PB0) has announced that early indications are that its PulmoBind™ product candidate has the potential for early diagnosis of Pulmonary Hypertension (PH) in the pediatric population. PH is a potentially life threatening and crippling disease; it is also very hard to diagnose. A typical diagnostic path for PH would include 2D Echocardiography with Doppler Flow studies, High Res CT of the chest, VP Lung Scanning and Cardiac Catheterization. Such diagnostic studies are expensive and in the case of Cardiac Catheterization, highly invasive. It is difficult to justify exposing infants to such a battery of tests without high prior clinical suspicion of PH and therefore justifies the need for simpler and possibly earlier diagnostic modalities. If our early experimental results are borne out by further experiments and trials, then PulmoBind™, as a simple, non-invasive screening test could be of particular benefit to the diagnosis of PH and other conditions afflicting the Pulmonary Vascular system in pediatric subjects where early stage diagnosis is perhaps of even more importance than it is in adults," stated Garry McCann, CEO Pulmo BioTech Inc.

Back to news